Aug 17, 2021 by Kody KesterHere's What This Label Expansion Means for AstraZeneca InvestorsThe recent decision by the EMA to approve Forxiga for the treatment of chronic kidney disease is a huge boost for the pharmaceutical company.
Aug 17, 2021 by Kody Kester3 Top Biotech Stocks to Buy in AugustEach of these companies makes for a great vehicle to play an aging demographic.
Aug 16, 2021 by Kody KesterAnalysts Love This Newly Formed Healthcare Company; Should You?Viatris' steady operating results and cheap valuation are two key reasons for its high one-year price target.
Aug 16, 2021 by Kody KesterIs This Financial Services Company a Buy Today?Prudential's strong second-quarter operating results are supported by a healthy macroeconomic backdrop.
Aug 13, 2021 by Kody KesterWhat Rinvoq's Positive News Means for AbbVieIf the drug can overcome JAK inhibitor-class concerns, it could capture share in the growing atopic dermatitis market.
Aug 12, 2021 by Kody Kester3 Reasons Why Williams Sonoma Will Do Just Fine in a Reopening EconomyWhile conventional wisdom dictates a return to some normalcy will be a major headwind to Williams Sonoma, things are not as they appear.
Aug 11, 2021 by Kody KesterCan Pfizer Seize Share in This Multibillion-Dollar Market?The answer ultimately depends on whether the uncertainty plaguing JAK inhibitors resolves positively.
Aug 10, 2021 by Kody KesterWhy Investors Should Consider This Asset ManagerHow did T. Rowe Price Group exceed analyst estimates in the second quarter and what does it mean?
Aug 10, 2021 by Kody KesterWhy This Insurer Is a Buy After a Strong Second QuarterTwo key factors helped Aflac beat analyst estimates for the second quarter.
Aug 6, 2021 by Kody KesterIs This Under-the-Radar Medical Device Company a Post-Earnings Buy?LeMaitre Vascular's operating fundamentals and balance sheet suggest it's a buy, depending on your objectives.
Aug 5, 2021 by Kody KesterIs This Medical-Device Company a Buy After Solid Earnings?The company's second-quarter results suggest it boasts positive operating fundamentals and a decent balance sheet.
Aug 4, 2021 by Kody KesterHow This Historic FDA Approval Benefits ViatrisHere's what the FDA's approval of Semglee, from Viatris and Biocon, means for the former.
Aug 4, 2021 by Kody KesterCan Ultomiris Continue to Drive Growth for AstraZeneca?The FDA recently approved Ultomiris as a treatment for paroxysmal nocturnal hemoglobinuria patients who are under 18, and it should get a similar label expansion in the E.U. soon.
Jul 31, 2021 by Kody KesterIs This Regional Bank a Buy After Missing Analyst Expectations?M&T Bank narrowly missed analyst expectations on revenue, but came up short on diluted EPS by a wider margin.
Jul 30, 2021 by Kody KesterIs This Regional Bank a Buy?KeyCorp's strong 2021 balance sheet and a $1.5 billion stock buyback plan, all while shares look undervalued, suggest the answer is "yes."
Jul 30, 2021 by Kody KesterThis In Vitro Diagnostics Company Is Poised to Capture Its Share of a Growing MarketIts new system marks a groundbreaking advance in the field of testing for bloodstream infections.
Jul 30, 2021 by Kody KesterHave $500? Here Are 2 High-Yielding Healthcare Stocks to ConsiderThese two companies offer impressive -- and safe -- yields for investors who like income.
Jul 30, 2021 by Kody KesterWhy the Recent UnitedHealth Group and Peloton Announcement Is a Win-WinThe deal will be beneficial for both companies and their customers.
Jul 30, 2021 by Kody KesterIs This Diagnostics Company a Buy After Blowing Away Earnings Estimates?Quest Diagnostics was the beneficiary of a faster than expected recovery in its base business in the second quarter.
Jul 30, 2021 by Kody KesterThis Drug's New Indication in China Will Be a Boost to AstraZenecaThe new approval to treat a form of lung cancer will be pivotal to dominating a massive market.
